000			01612 a2200433 4500
005			20250516043631.0
264		0	_c20120427
008			201204s 0 0 eng d
022			_a1878-1705
024	7		_a10.1016/j.intimp.2011.06.005 _2doi
040			_aNLM _beng _cNLM
100	1		_aThaher, Firas
245	0	0	_aDifferential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro. _h[electronic resource]
260			_bInternational immunopharmacology _cNov 2011
300			_a1724-31 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal _xpharmacology
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCytokines _xantagonists & inhibitors
650	0	4	_aCytotoxicity, Immunologic _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEtanercept
650	0	4	_aFemale
650	0	4	_aFlow Cytometry
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xpharmacology
650	0	4	_aInfliximab
650	0	4	_aMacrophages _xdrug effects
650	0	4	_aMale
650	0	4	_aNatural Killer T-Cells _xdrug effects
650	0	4	_aReceptors, Tumor Necrosis Factor
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
650	0	4	_aYoung Adult
700	1		_aPlankenhorn, Sandra
700	1		_aKlein, Reinhild
773	0		_tInternational immunopharmacology _gvol. 11 _gno. 11 _gp. 1724-31
856	4	0	_uhttps://doi.org/10.1016/j.intimp.2011.06.005 _zAvailable from publisher's website
999			_c20958496 _d20958496